2016 American Transplant Congress
The Optimal Time Point for Steroid Withdrawal After Kidney Transplantation Is One Year After Engraftment.
The optimal time of steroid withdrawal after kidney transplantation remains elusive, since RCTs can evaluate one predefined time point. Thus we analyzed all first kidney…2016 American Transplant Congress
Graft Survival of Steroid-Avoidance Protocols in Pediatric Kidney Transplantation[mdash]A Propensity Score Analysis.
Purpose: This study investigated whether steroid avoidance-protocols adversely influence allograft survival among pediatric kidney transplant recipients at high levels of immunologic risk.Methods: A retrospective cohort…2016 American Transplant Congress
Early Steroid Withdrawal in African American Kidney Transplant Recipients: A Propensity Score Matching Analysis.
Objective: The aim of this study was to assess the safety of steroid withdrawal in African American (AA) kidney transplant (KTX) recipients.Methods: Longitudinal cohort study…2016 American Transplant Congress
Everolimus Plus Reduced-Exposure Cyclosporin versus Mycophenolic Acid Plus Cyclosporin: Seven-Year Follow-Up of Australia and New Zealand Kidney Transplant Recipients in the A2309 Study.
A2309 was a 2-year, phase III randomized controlled trial evaluating the effect on graft and patient outcomes of three groups:1.5mg everolimus plus low exposure cyclosporine…2016 American Transplant Congress
Everolimus/Low Tacrolimus(TAC) Compared to MPA/RegularTAC for Renal Transplantation in the Elderly Recipient – Preliminary Analysis of the nEverOld Trial.
In the last decade, elderly patients (≥60y) have been more frequently listed for renal transplantation. From 2007 to 2014 the percentage of elderly renal transplant…2016 American Transplant Congress
Comparison of Clinical Outcomes of Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients.
To examine the utilization and clinical outcomes of belatacept in the real clinical setting, a retrospective cohort study was conducted using SRTR data that compared…2016 American Transplant Congress
Successful Treatment of Hepatitis C in Renal Transplant Recipients with Directly Acting Antiviral Agents.
Background: Hepatitis C infection (HCV) in kidney transplant (KTx) recipients has been shown to be a risk factor for decreased patient and allograft survival. With…2016 American Transplant Congress
Analysis of FSGS (Focal Segmental Glomerulosclerosis) Recurrence After Renal Transplantation.
Nephrology-Division, Hospital do Rim - UNIFESP, São Paulo, Brazil.
Purpose: To describe clinical-laboratorial profile and outcome of patients diagnosed with recurrent FSGS submitted to plasmapheresis.Methods: Retrospective single-center cohort study including all patients with recurrent…2016 American Transplant Congress
Insights into the Treatment of Post-Transplant Focal Glomerulosclerosis: Experience Gained from a Concise Diagnostic and Management Protocol.
Background: Recurrence of Focal Glomerulosclerosis (FSGS) after kidney transplantation is associated with poor graft survival. We present results from a concise diagnostic and management protocol…2016 American Transplant Congress
Recurrence of FSGS Post Kidney Transplantation: Salvage Therapy with ACTHAR® Gel.
Transplant, Emory University, Atlanta, GA.
Recurrence of FSGS post kidney transplantation: Salvage therapy with ACTHAR® gel.Introduction:Recurrence of FSGS post kidney transplantation may reach 25-50%. Failure of treatment or incomplete remission…
American Transplant Congress abstracts